drugset / Trial / NCT01085084
A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus Arthritis
RandomizedParallel-groupTriple-blindTreatment
Summary
The study aims to evaluate the safety and clinical effect of daily oral treatment with laquinimod capsules (0.5 milligrams \[mg\] and 1 mg) in participants with active lupus arthritis. Laquinimod is a novel immunomodulating drug which is currently in advanced stages of development by Teva Pharmaceuticals Ltd. for Multiple Sclerosis.
Timeline
- Start
- 2010-10-04
- Primary completion
- 2012-11-12
- Completion
- 2012-11-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Laquinimod | Small molecule | 0.5 mg | Oral |
| Subject | Laquinimod | Small molecule | 1 mg | Oral |